PMID- 30267217
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20190102
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 275
IP  - 11
DP  - 2018 Nov
TI  - The identification of induction chemo-sensitivity genes of laryngeal squamous 
      cell carcinoma and their clinical utilization.
PG  - 2773-2781
LID - 10.1007/s00405-018-5134-x [doi]
AB  - PURPOSE: To identify potential molecular markers for induction chemotherapy of 
      Laryngeal squamous cell carcinoma (LSCC). METHODS: Differently expressed genes 
      between chemo-sensitive group (seven cases) and chemo-insensitive (five cases) 
      group after induction chemotherapy by TPF were identified by microarrays. Bayes 
      network and Random forest analyses were employed to identify core genes for 
      induction chemotherapy. The diagnostic value of these core genes was also 
      evaluated by ROC analysis. RESULTS: Six genes (SPP1, FOLR3, KYNU, LOC653219, ADH7 
      and XAGE1A) are highly expressed, while seven gene (CADM1, NDUFA4L2, CCND2, 
      RARRES3, ERAP2, LYD6 and CNTNAP2) present significantly low expression. Among 
      these genes, genes CADM1, FOLR3, KYNU, and CNTNAP2 are core candidates for LSCC 
      chemo-sensitivity. And that the low expression of CADM1 may result in 
      chemo-sensitivity, which leads to high expression of gene FOLR3 and KYNU, and low 
      expression of gene CNTNAP2. Besides, ROC analysis shows that these four genes 
      exhibit effective diagnostic value for induction chemo-sensitivity. CONCLUSIONS: 
      CADM1 may be a potential molecular marker for LSCC induction chemotherapy, while 
      CADM1, FOLR3, KYNU, and CNTNAP2 may provide essential guidance for LSCC diagnosis 
      and follow-up treatment strategies.
FAU - Li, Lianhe
AU  - Li L
AUID- ORCID: 0000-0002-6810-9737
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China.
AD  - Central Hospital of Chaoyang, Liaoning, China.
FAU - Wang, Ru
AU  - Wang R
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China.
FAU - He, Shizhi
AU  - He S
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China.
FAU - Shen, Xixi
AU  - Shen X
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China.
FAU - Kong, Fanyong
AU  - Kong F
AD  - The Hospital of Shunyi District Beijing, Beijing, China.
FAU - Li, Shuchun
AU  - Li S
AD  - School of Pharmaceutical Sciences, Minzu University of China, Beijing, China.
FAU - Zhao, Huanhu
AU  - Zhao H
AD  - School of Pharmaceutical Sciences, Minzu University of China, Beijing, China.
FAU - Lian, Meng
AU  - Lian M
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China. 
      lianmeng19861222@163.com.
FAU - Fang, Jugao
AU  - Fang J
AD  - Beijing Tongren Hospital, Capital Medical University, Beijing, China. 
      fangjugao@163.com.
LA  - eng
GR  - XMLX201311/Beijing Municipal Administration of Hospitals Clinical Medicine 
      Development of Special Funding Support/
GR  - PX2018009/Sponsored by Beijing Municipal Administration of Hospitals Incubating 
      Program/
GR  - 17JL76/The Basic-Clinical Cooperation Fund, Capital Medical University/
GR  - JQ17031/The Golden Bridge Project, Beijing/
PT  - Journal Article
DEP - 20180928
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (CADM1 protein, human)
RN  - 0 (CNTNAP2 protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (Cell Adhesion Molecule-1)
RN  - 0 (FOLR3 protein, human)
RN  - 0 (Genetic Markers)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA, Complementary)
SB  - IM
MH  - Aged
MH  - Carcinoma, Squamous Cell/*drug therapy/*genetics
MH  - Carrier Proteins/genetics
MH  - Cell Adhesion Molecule-1/genetics
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Expression Profiling
MH  - Genetic Markers
MH  - Humans
MH  - *Induction Chemotherapy
MH  - Laryngeal Neoplasms/*drug therapy/*genetics
MH  - Male
MH  - Membrane Proteins/genetics
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Nerve Tissue Proteins/genetics
MH  - RNA, Complementary/metabolism
OTO - NOTNLM
OT  - Chemo-sensitivity
OT  - Induction chemotherapy
OT  - Laryngeal squamous cell carcinoma
OT  - Molecular marker
EDAT- 2018/09/30 06:00
MHDA- 2019/01/03 06:00
CRDT- 2018/09/30 06:00
PHST- 2018/07/15 00:00 [received]
PHST- 2018/09/14 00:00 [accepted]
PHST- 2018/09/30 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2018/09/30 06:00 [entrez]
AID - 10.1007/s00405-018-5134-x [pii]
AID - 10.1007/s00405-018-5134-x [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2773-2781. doi: 
      10.1007/s00405-018-5134-x. Epub 2018 Sep 28.